- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
3D Printing Could Improve Drug Discovery and Development
3D printing of tumors could provide a more physiological environment to boost cancer drug discovery and development.
Drexel’s Wei Sun, PhD, Albert Soffa chair professor in the College of Engineering, has devised a method for 3D printing tumors that could soon be taking cancer research out of the petri dish.
Using a mixture of cervical cancer cells and a hydrogel substance that resembles an ointment balm, Sun can print out a tumor model that can be used for studying their growth and response to treatment. This living model will give cancer researchers a better look at how tumors behave and a more accurate measure of how they respond to treatment.
“This is the first time to report that one can build a 3D in vitro tumor model through 3D Printing technology,” said Sun, the director of Drexel’s research center at the Shanghai Advanced Research Institute. “This may lead to a new paradigm for cancer research and for individual cancer therapies. We have developed a technological platform and would like to work with biologists and pathologists to encourage them to use the developed platform for 3D biology and disease studies.”
Read the press release:
Source: Drexel News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
